EXTON, PA — Castle Creek Biosciences, Inc. announced that Matthew Gantz has been appointed President and Chief Executive Officer. He will also serve as a member of the Company’s Board of Directors. Mr. Gantz succeeds John Maslowski, who will continue to serve the company as Chief Operating Officer.
“Matthew’s leadership, patients-first focus and global commercial experience will complement Castle Creek’s proven expertise in cell and gene therapies that continues to distinguish the Company as a rising leader in the field and a valued contributor to Paragon Biosciences’ expanding life sciences portfolio,” said Jeff Aronin, Founder and Chairman of Castle Creek Biosciences, Inc. and Founder, Chairman and Chief Executive Officer of Paragon Biosciences, LLC. “Matthew is an outstanding addition to Castle Creek’s executive team as the Company continues to develop and advance novel personalized treatments that offer the potential to help patients suffering from devastating genetic disorders to live longer, healthier lives.”
“I am honored to join Castle Creek at this important time and excited to work with their accomplished team to further progress and expand our cell-based, gene therapy pipeline led by our Phase 3 study for patients suffering from recessive dystrophic epidermolysis bullosa (RDEB),” said Mr. Gantz. “Our proprietary autologous fibroblast platform and in-house commercial scale manufacturing facility uniquely position us for growth, enabling us to potentially develop promising new therapies that address unmet medical needs. Our goal is to make a difference in the lives of patients and their families who currently have few or no treatment options.”
An accomplished life sciences executive with more than 25 years of experience in the specialty biopharmaceutical and medical device industries, Mr. Gantz previously served as Chief Executive Officer of OxThera AB. He has also held executive leadership positions with BTG plc, Acureon Pharmaceuticals, Inc., Hydra Biosciences, Chiron Corporation, PathoGenesis Corporation and Abbott Laboratories. Mr. Gantz is currently a board member of Swedish Orphan Biovitrum AB, a publicly-traded, international rare disease company, and the Marine Corps Scholarship Foundation, a not-for-profit organization that provides scholarships for the children of Marines to pursue secondary education. He received his B.A. in history from Princeton University, his M.B.A. from Harvard Business School and served as an infantry officer in the U.S. Marine Corps.
Headquartered in Exton, Castle Creek Biosciences, Inc. is a privately held, clinical-stage cell and gene therapy company leveraging its proprietary fibroblast technology platform to develop and commercialize disease-modifying therapies for patients suffering from orphan conditions for which there is a lack of available treatment options,
Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.
Disclosure: This site contains affiliate links to products, identified by the icon. MyChesCo may receive a commission for purchases made through these links.